Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ONCODESIGN Achieves UCB Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ONCODESIGN Achieves UCB Milestone

UCB obtains worldwide rights to compounds for neurological disorders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ONCODESIGN has reached a major milestone in its joint discovery collaboration with UCB relating to its Nanocyclix technology on a kinase target selected by UCB. The collaboration, dating back to October 2013, aims to develop therapies to treat neurological disorders. UCB will now obtain worldwide development and commercialization rights to the compounds. Oncodesign is eligible to receive further research funding, product-related development, regulatory and commercial milestones, as well as royalties.
 
Nanocyclix is a medicinal chemistry technology based on small molecule macrocyclisation that provides solutions to accessing potent and highly selective kinase inhibitors that can readily cross the Blood-Brain-Barrier.
 
“In just over a year, the progress achieved in our early research collaboration has convinced UCB to take a full license on the program and enter into an additional multi-year research program. We are very excited to continue our partnership. Identifying inhibitors that are potent and selective – to avoid side effects for the intended chronic use – and that readily enter into the brain after oral application have been major challenges for many years in kinase research. The current license exercised by UCB further validates Nanocyclix as a “next generation” kinase inhibitor technology that allows to tackle kinases in notoriously difficult fields,” said Jan Hoflack, Ph.D., chief scientific officer of Oncodesign.
 
“Our collaboration with Oncodesign so far has been extremely positive, and this agreement was the natural next step,” said Neil Weir, UCB’s head of Discovery Research. “Our discovery teams really look forward to working with Oncodesign even more closely in the coming months. Oncodesign’s strong experience and expertise in kinase inhibitor research will undoubtedly help deepen our understanding in this crucial area and bring value to people suffering from severe neurological diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics